ReviewCureus2025
Maximizing the Longevity and Volume Retention of Fat Grafts: Advances in Clinical Practice.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Large-Volume Breast Autologous Fat Transfer Entirely Under Tumescent Anesthesia: Experience With 87 Patients Over 6 Years.Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2026Article
- Radiological Findings Post Autologous Fat Grafting and Breasts Procedures: Avoiding False Positive Results.ANZ journal of surgery · 2026Review
- Injectable Scaffolds for Adipose Tissue Reconstruction.Gels (Basel, Switzerland) · 2026Review
- Advancing fat graft survival: from adipose-derived stem cell mechanisms to next-generation regenerative strategies.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autologous fat grafting (AFG) is increasingly utilized in aesthetic and reconstructive surgery owing to its biocompatibility, regenerative properties, and ease of harvest. However, inconsistent graft retention rates pose a persistent clinical challenge. This review explores contemporary advancements aimed at improving fat graft survival and volume retention. Biological enhancements, such as platelet-rich plasma (PRP), stromal vascular fraction (SVF), and adipose-derived stem cells (AdSCs), have demonstrated efficacy in promoting angiogenesis, reducing fibrosis, and improving graft integration. Emerging strategies, including vitamin E (VE) augmentation, compact fat grafting, and soluble molecule preconditioning with agents like deferoxamine (DFX) and vascular endothelial growth factor (VEGF), have shown promise in experimental and clinical models. The synergistic use of PRP and AdSCs yields higher growth factor expression, enhancing tissue viability. Innovations like Botulinum Toxin-A (BoNTA) for muscle immobilization, concentrated de-oiled fat (CDF), and biodegradable scaffolds further contribute to improved outcomes. Site-specific adaptations - for craniofacial, breast, and gluteal regions - demonstrate tailored approaches that enhance regional graft viability. Despite these advancements, standardization remains a barrier due to methodological heterogeneity in harvesting, processing, and application. Furthermore, while preliminary results from clinical trials are encouraging, long-term data and larger cohorts are required to validate safety and effectiveness. Future research should focus on optimizing stem cell enrichment protocols, biomaterial integration, and understanding molecular pathways that govern graft survival. Collectively, these evolving strategies represent a significant leap forward in maximizing the functional and aesthetic benefits of fat grafting, heralding a new era of regenerative plastic surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.